Summary
We examined eight tricyclic antidepressants (doxepin, amitriptyline, clomipramine, imipramine, trimipramine, nortriptyline, desipramine and protriptyline) and four nontricyclic antidepressants (mianserin, nomifensin, iprindole and zimelidine) in terms of their effects on serotonergic and adrenergic receptors by direct binding assays.3H-WB-4101 (0.22 nM) served as a label for postsynaptic alpha receptors while3H-clonidine (0.2 nM) served to label presynaptic alpha receptors in the frontal cortex of the calf.3H-dihydroalprenolol (3H-DHA) (0.5 nM) was used to label the beta1 adrenoceptors in the calf frontal cortex and beta2 adrenoceptors in the calf cerebellar cortex.3H-d-Lysergic acid diethylamide (3H-LSD) (2 nM) and3H-serotonin (3H-5HT) (0.5 nM) were used to label the serotonergic receptors in the calf frontal cortex.
The results show that at drug concentrations which occur clinically in the plasma water, most of the tertiary amine tricyclics significantly inhibited3H-WB-4101,3H-LSD and3H-5HT binding. None of the antidepressants tested had any significant effect on3H-DHA binding. The secondary amine tricyclics as a group were not potent in inhibiting the binding of all four radiolabelled ligands. The nontricyclic antidepressant mianserin was potent in inhibiting the binding of3H-WB-4101,3H-clonidine,3H-LSD and3H-5HT. We suggest that the differences between the effects of the antidepressants on adrenergic and serotonergic receptors may be responsible for the differences in their therapeutic efficacies and side effects.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Apperley, E., Humphrey, P. P. A., Levy, G. P.: Receptors for 5-hydroxytryptamine and noradrenaline in rabbit isolated ear artery and aorta. Br. J. Pharmacol.58, 211–221 (1976)
Ashcroft, G. W., Crawford, T. B. B., Eccleston, D., Sharman, D. F., McDougall, E. J., Stanton, J. B., Binns, J. K.: 5-Hydroxyindole compounds in the cerebrospinal fluid of patients with psychiatric or neurological diseases. Lancet1966II, 1049–1052
Banerjee, S. P., Kung, L. S., Riggi, S. J., Chanda, S. K.: Development of β-adrenergic receptor subsensitivity by antidepressants. Nature268, 455–456 (1977)
Baumann, P. A., Maitre, L.: Blockade of presynaptic α-receptors and of amine uptake in the rat brain by the antidepressant mianserine. Naunyn-Schmiedeberg's Arch. Pharmacol.300, 31–37 (1977)
Bennett, J. P., Snyder, S. H.: Serotonin and lysergic acid diethylamide binding in rat brain membranes: relationship to postsynaptic serotonin receptors. Mol. Pharmacol.12, 373–389 (1976)
Bergstrom, D. A., Kellar, K. J.: Adrenergic and serotonergic receptor binding in rat brain membranes: relationship to postsynaptic serotonin receptors. Mol. Pharmacol.12, 373–389 (1976)
Bergstrom, D. A., Kellar, K. J.: Adrenergic and serotonergic receptor binding in rat brain after chronic desmethylimipramine treatment. J. Pharmacol. Exp. Ther.209, 256–261 (1979)
Carlsson, A., Corrodi, H., Fuxe, K., Hokfelt, T.: Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-α-ethyl-metatyramine. Eur. J. Pharmacol.5, 357–366 (1969a)
Carlsson, A., Corrodi, H., Fuxe, K., Hokfelt, T.: Effects of some antidepressant drugs on the depletion of intranseuronal brain catecholamine stores caused by 4-α-dimethyl-meta-tyramine. Eur. J. Pharmacol.5, 367–373 (1969b)
Clements-Jewery, S.: The development of cortical β-adrenoceptor subsensitivity in the rat by chronic treatment with trazodone, doxepin and mianserine. Neuropharmacology17, 779–781 (1978)
Cooper, T. B., Simpson, G. M., Lee, J. H.: Thymoleptic and neuroleptic drug plasma levels in psychiatry: current status. In: International review of neurobiology, Vol. 19. New York: Academic 1976
Coppen, A., Prange, A. J., Whybrow, P. C., Noguera, R.: Abnormalities of indoleamines in affective disorders. Arch. Gen. Psychiatry26, 474–478 (1972)
Denker, S. J., Malm, U., Roos, B.-E., Werdinius, B.: Acid monoamine metabolites of cerebrospinal fluid in mental depression and mania. J. Neurochem.13, 1545–1548 (1966)
Domenjoz, R., Theobald, W.: Zur Pharmakologie des Tofranil [N-(3-dimethylaminopropyl)-iminobenzylhydroachlorid]. Arch. Int. Pharmacodyn.120, 450–489 (1959)
Fillion, G. M. B., Rousselle, J.-C., Fillion, M.-P., Beaudoin, D. M., Goiny, M. R., Deniau, J.-M., Jacob, J. J.: [3H]-5-hydroxytryptamine to brain synaptosomal membranes: comparison with [3H] lysergic acid diethylamide binding. Mol. Pharmacol.14, 50–59 (1979)
Friedel, R. O., Veith, R. C., Bloom, V., Bielski, R. J.: Desipramine plasma levels and clinical response in depressed outpatients. Comm. Psychopharmacol.3, 81–87 (1979)
Fuxe, K., Ögren, S.-O., Agnati, L. F., Gustafsson, J. Å., Jonsson, G.: On the mechanism of action of the antidepressant drugs amitriptyline and nortriptyline. Evidence for 5-hydroxytryptamine receptor blocking activity. Neurosci. Lett.6, 339–343 (1977)
Garfinkel, P. E., Warsh, J. J., Stancer, H. C., Godse, D. D.: CNS monoamine metabolism in bipolar affective disorder. Arch. Gen. Psychiatry34, 735–739 (1977)
Glowinski, J., Axelrod, J.: Effect of drugs on the uptake, release and metabolism of3H-norepinephrine in the rat brain. J. Pharmacol. Exp. Ther.149, 43–49 (1965)
Goodlet, I., Mireylees, S. E., Sugrue, M. F.: Effects of mianserin, a new antidepressant, on the in vitro and in vivo uptake of monoamines. Br. J. Pharmacol.61, 307–313 (1977)
Goodwin, F. K., Beckmann, H.: Urinary MHPG in unipolar and bipolar affective disorders. Sci. Proc. Am. Psychiat. Ass.128, 96–97 (1975)
Gram, L. F., Reisby, N., Ibsen, I., Nagy, A., Dencker, S. J., Bech, P., Petersen, G. O., Christiansen, J.: Plasma levels and antidepressive effect of imipramine. Clin. Pharmacol. Ther.19, 318–324 (1975)
Green, J. P., Maayaini, S.: Tricyclic antidepressant drugs block histamine H2 receptor in brain. Nature269, 163–165 (1977)
Harden, T. K., Wolfe, B. B., Molinoff, P. B.: Binding of iodinated beta adrenergic antagonists to proteins derived from rat heart. Mol. Pharmacol.12, 1–15 (1975)
Iversen, L. L.: Uptake processes for biogenic amines. In: Handbook of Psychopharmacology, vol. 3 (L. L. Iversen, S. D. Iversen, S. H. Snyder, eds.), pp. 381–442. New York: Plenum 1975
Kanof, P. D., Greengard, P.: Brain histamine receptors as targets for antidepressant drugs. Nature272, 329–333 (1978)
Kapur, H., Mottram, D. R.: The interaction of WB4101, and other α-adrenoceptor antagonists, on 5-hydroxytryptamine receptors. J. Pharm. Pharmacol.31, 337–338 (1979)
Kragh-Sorenson, P., Hansen, C. E., Braestrup, P. C., Hvidberg, E. F.: Self-inhibiting action of nortriptyline antidepressant effect at high plasma levels. Psychopharmacologia45, 305–312 (1976)
Maas, J. W.: Catecholamines and depression: a further specification of the catecholamine hypothesis of the affective disorders. In: Catecholamines and Behaviour 2 (A. J. Friedhoff, ed.), pp. 119–133. New York: Plenum 1975
Maas, J. W.: Clinical and biochemical heterogeneity of depressive disorders. Ann. Intern. Med.88, 556–563 (1978)
Maas, J. W., Fawcett, J. A., Dekirmenjian, H.: Catecholamine metabolism, depressive illness and drug response. Arch. Gen. Psychiat.26, 252–262 (1972)
Maguire, M. E., Wiklund, R. A., Anderson, H. J., Gilman, A. G.: Binding of [125I] Iodohydroxybenzylpindolol to putative β-adrenergic receptors of rat glioma cells and other cell clones. J. Biol. Chem.251, 1221–1231 (1976)
Mendels, J., Frazer, A., Fitzgerald, R. G., Ramsey, T. A., Stokes, J. W.: Biogenic amine metabolites in cerebrospinal fluid of depressed and manic patients. Science175, 1380–1382 (1972)
Montgomery, S. A., Braithwaite, R. A., Crammer, J. I.: Routine nortriptyline levels in treatment of depression. Br. Med. J.1977II, 166–167
Psychoyos, S.: H1- and H2-histamine receptors linked to adenylate cyclase in cell-free preparations of guinea pig cerebral cortex. Life Sci.23, 2155–2162 (1978)
Raisman, R., Briley, M., Langer, S. Z.: High-affinity3H-imipramine binding in rat cerebral cortex. Eur. J. Pharmacol.54, 307–308 (1979)
Rehavi, M., Sokolovsky, M.: Multiple binding sites of tricyclic antidepressant drugs to mammalian brain receptors. Brain Res.149, 525–529 (1978)
Rehavi, M., Maayani, S., Goldstein, L., Assael, M., Sokolovsky, M.: Antimuscarinic properties of antidepressants: dibenzepin (Noveril). Psychopharmacology54, 35–38 (1977)
Richelson, E.: Tricyclic antidepressants block histamine H1 receptors of mouse neuroblastoma cells. Nature274, 176–177 (1978)
Richelson, E.: Tricyclic antidepressants and histamine H1 receptors. Mayo Clin. Proc.54, 669–674 (1979)
Rosenblatt, J. E., Pert, C. B., Tallman, J. F., Pert, A., Bunney, W. E., Jr.: The effect of imipramine and lithium on α- and β-receptor binding in rat brain. Brain Res.160, 186–191 (1979)
Sarai, K., Frazer, A., Brunswick, D., Mendels, J.: Desmethylimipramine-induced decrease in β-adrenergic binding in rat cerebral cortex. Biochem. Pharmacol.27, 2179–2181 (1978)
Saxena, P. R., van Houwelingen, P., Bonta, I. L.: The effects of mianserin hydrochloride on the vascular responses evoked by 5-hydroxytryptamine and related vasoactive substances. Eur. J. Pharmacol.13, 295–305 (1971)
Schildkraut, J. J.: Norepinephrine metabolites as biochemical criteria for classifying depressive disorders and predicting responses to treatment: preliminary findings. Am. J. Psychiatry130, 695–698 (1973)
Sigg, E. B.: Pharmacological studies with Tofranil. Can. Psychiatr. Assoc. J.4, S75-S85 (1959)
Snyder, S. H., Yamamura, H. I.: Antidepressants and the muscarmic acetylcholine receptor. Arch. Gen. Psychiatry34, 236–239 (1977)
Tang, S. W., Helmeste, D. M., Stancer, H. C.: Interaction of antidepressants with clonidine on rat brain total 3-methoxy-4-hydroxyphenylglycol. Can. J. Physiol. Pharmacol.57, 435–437 (1979)
Titeler, M., Tedesco, J. L., Seeman, P.: Selective labeling of presynaptic receptors by3H-dopamine,3H-apomorphine and3H-clonidine; labeling of post-synaptic sites by3H-neuroleptics. Life Sci.23, 587–592 (1978)
U'Prichard, D. C., Greenberg, D. A., Snyder, S. H.: Binding characteristics of a radiolabeled agonist and antagonist at central nervous system alpha-noradrenergic receptors. Mol. Pharmacol.13, 454–473 (1977)
U'Prichard, D. C., Charness, M. E., Robertson, D., Snyder, S. H.: Prazosin: differential affinities for two populations of α-noradrenergic receptor binding sites. Eur. J. Pharmacol.50, 87–89 (1978a)
U'Prichard, D. C., Bylund, D. B., Snyder, S. H.: (±)-[3H]Epinephrine and (−)-[3H]Dihydroalprenolol binding toβ 1 andβ 2 noradrenergic receptors in brain, heart, and lung membranes. J. Biol. Chem.253, 5090–5102 (1978b)
U'Prichard, D. C., Greenberg, D. A., Sheehan, P. P., Snyder, S. H.: Tricyclic antidepressants: therapeutic properties and affinity for α-noradrenergic receptor binding sites in the brain. Science199, 197–198 (1978c)
van Praag, H. M., Korf, J., Puite, J.: 5-Hydroxyindoleacetic acid levels in the cerebrospinal fluid of depressive patients treated with probenecid. Nature225, 1259–1260 (1970)
Whitaker, P. M., Seeman, P.: High-affinity3H-serotonin binding to caudate: inhibition by hallucinogens and serotoninergic drugs. Psychopharmacology59, 1–5 (1978a)
Whitaker, P. M., Seeman, P.: Selective labeling of serotonin receptors by d-[3H]lysergic acid diethylamide in calf caudate. Proc. Natl. Acad. Sci.75, 5783–5787 (1978b)
Whyte, S. F., MacDonald, A. J., Naylor, G. J., Moody, J. P.: Plasma concentrations of protriptyline and clinical effects in depressed women. Brit. J. Psychiat.128, 384–390 (1976)
Yates, C. M., Todrick, A., Tait, A. C.: Aspects of the clinical chemistry of desmethylimipramine in man. J. Pharm. Pharmacol.15, 432–439 (1963)
Author information
Authors and Affiliations
Additional information
Supported by the Canada Medical Research Council and the Ontario Mental Health Foundation
Rights and permissions
About this article
Cite this article
Tang, S.W., Seeman, P. Effect of antidepressant drugs on serotonergic and adrenergic receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 311, 255–261 (1980). https://doi.org/10.1007/BF00569405
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00569405